Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
